ClinicalTrials.Veeva

Menu

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

AbbVie logo

AbbVie

Status and phase

Completed
Phase 4

Conditions

Chronic Pancreatitis
Cystic Fibrosis

Treatments

Drug: CREON

Study type

Interventional

Funder types

Industry

Identifiers

NCT05069597
M21-432

Details and patient eligibility

About

Exocrine pancreatic insufficiency (EPI) is a condition that is caused by the inadequate pancreatic enzymes needed for normal digestion and is commonly associated with a wide range of chronic diseases, including cystic fibrosis (CF), chronic pancreatitis (CP), and pancreatic cancer. This study will assess clinical symptoms when participants with CF or CP are treated with Creon with alternate source of active drug.

Creon is an approved drug for the treatment of EPI. This study is subject-blinded which means participants will not know the source of the study drug they are given. Approximately 30 adult participants with CF or CP will be enrolled at approximately 15 sites across the Unites States.

Participants will receive oral capsules of CREON for 113 days and will be followed for 30 days.

Participants will attend regular visits during the study at a hospital or clinic or via telemedicine. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Previous diagnosis of cystic fibrosis (CF) or chronic pancreatitis (CP).
  • Previous diagnosis of exocrine pancreatic insufficiency (EPI) that is currently clinically controlled.
  • Total Symptom Score (TSS) < 1.8 on Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) at Screening.

Exclusion criteria

  • Malignancy involving the digestive tract in the last 5 years, or other significant disease or medical condition that may interfere with EPI symptom assessment.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Sequential Assignment

Masking

Single Blind

30 participants in 2 patient groups

Run-in Period: Creon-ABT
Experimental group
Description:
Participants will receive Creon-ABT daily for 28 days.
Treatment:
Drug: CREON
Treatment Period: Creon-AAPIS
Experimental group
Description:
Participants will receive Creon-AAPIS daily for 85 days.
Treatment:
Drug: CREON

Trial documents
2

Trial contacts and locations

22

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems